Internal Medicine, Hematology & Oncology · Durham, NC
NPI
1912080169
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
Duke University Medical Ctr
Durham, NC, 27710
Phone (919) 620-4467
Groups this clinician bills Medicare through
Medicare paid, 2024
$28K
590 services
Medicare patients, 2024
161
Average age 73
Drug cost, 2024
$3.1M
410 prescriptions
Company payments, 2025
$22K
From 6 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Carlos M Decastro III was code G2211 (visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's), 245 times for 116 patients. In total Carlos M Decastro III billed 590 services in 10 codes, and Medicare paid $28K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-08-13.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 245 | 116 | $11.50 | $2,817 |
| 99214 Office E&M - Established | Office | 239 | 118 | $62.02 | $15K |
| 99215 Office E&M - Established | Office | 58 | 45 | $92.11 | $5,342 |
| 99205 Office E&M - New | Office | 36 | 36 | $120.56 | $4,340 |
By year: 2022 $60K for 757 services; 2023 $35K for 446 services; 2024 $28K for 590 services.
Medicare prescription drug claims, 2024
In 2024, the drug Carlos M Decastro III prescribed most often to Medicare patients was Imatinib Mesylate, with 41 prescriptions and refills. In total Carlos M Decastro III wrote 410 Medicare prescriptions that cost $3.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Imatinib Mesylate Generic | 41 | 41 | Under 11 | $6,225 |
| Inqovi Decitabine/Cedazuridine | 35 | 38 | Under 11 | $246K |
| Cyclosporine Modified Cyclosporine, Modified | 30 | 34 | Under 11 | $2,533 |
| Jakafi Ruxolitinib Phosphate | 29 | 29 | Under 11 | $490K |
| Venclexta Venetoclax | 24 | 24 | Under 11 | $207K |
| Ondansetron Hcl Generic | 22 | 22 | 11 | $91.52 |
| Tasigna Nilotinib Hcl | 15 | 15 | Under 11 | $225K |
| Prednisone Generic | 14 | 16 | Under 11 | $54.94 |
| Acyclovir Generic | 14 | 14 | Under 11 | $152 |
| Iclusig Ponatinib Hcl | 13 | 13 | Under 11 | $282K |
| Empaveli Pegcetacoplan | 13 | 13 | Under 11 | $615K |
| Vonjo Pacritinib Citrate | 12 | 12 | Under 11 | $296K |
| Brukinsa Zanubrutinib | 11 | 11 | Under 11 | $147K |
Brand drugs: 185 claims; generic drugs: 225 claims; opioid claims: 13.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Carlos M Decastro III $22K ($13K in general payments such as food, travel and fees and $9,461 for research) from 6 companies. The largest payer was Regeneron Pharmaceuticals, Inc. with $9,006.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.